SEARCH

SEARCH BY CITATION

References

  • 1
    Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2:528530.
  • 2
    Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68:105112.
  • 3
    Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96:447449.
  • 4
    Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985; 145:13131314.
  • 5
    Lau JYN, Lai CL, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73:911917.
  • 6
    Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Brechot C, et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988; 33:11851191.
  • 7
    Liang RHS, Lok ASF, Lai CL, Chan TK, Tood D, Chiu EKW. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8:261270.
  • 8
    Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy—report of a prospective study. Gastroenterology 1991; 100:182188.
  • 9
    Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13:1420.
  • 10
    Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999; 81:6974.
  • 11
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy—a prospective study in 305 patients. Hepatogastroenterology 1999; 46:29252930.
  • 12
    Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17:394398.
  • 13
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87:1202.
  • 14
    Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997: 8(Suppl 1):107109.
  • 15
    Faggioli P, Paschale M, Tocci A, Luoni M, Fava S, De Paoli A, Tosi A, Cassi E. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Haematologica 1997; 82:3842.
  • 16
    Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:10091022.
  • 17
    Sagnelli E, Manzillo G, Mario G, Pasquale G, Felaco FM, Filippini P, Izzo CM, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2:395397.
  • 18
    Scullard GH, Smith CI, Merigan TC, Roinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81:987991.
  • 19
    Lam KC, Ching LL, Ng RP, Trepo C, Wu PC. Deleterious effect of predinosolone in HBsAg-Positive chronic active hepatitis. N Engl J Med 1981; 304:380386.
  • 20
    Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, Waggoner JG, et al. A short course of prednisolone in chronic type B hepatitis. Ann Intern Med 1986; 104:1217.
  • 21
    Lee SD, Tong MJ, Wu JC, Lin HC, Tsai YT, Lo KJ. A randomized double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B. J Hepatol 1991; 12:146150.
  • 22
    Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6:173179.
  • 23
    Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80:687692.
  • 24
    Tur-Kaspa R, Burk RD, Shaul Y, Shafrits DA. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci U S A 1986; 83:16271631.
  • 25
    Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16:1318.
  • 26
    Ohtsu T, Sai T, Oka M, Sugai Y, Tobinai K. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991; 21:360365.
  • 27
    Sparano JA, Wiernik PH, Leaf A, Dutcher JP. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration. J Clin Oncol 1993: 11:10711079.
  • 28
    Cabanillas F. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience. Semin Oncol 1993; 19:1113.
  • 29
    Herbrecht R, Damonte JC, Dufoure P, Maloisel F, Liuk L, Ortiz S, Bergerat JP, et al. Etoposide, ifosfamide and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphoma after failure of the NLH 84 regimen. Semin Oncol 1992; 197:710.
  • 30
    Berd D, Cornog J, Decont RC, Levitt M, Bertino JR. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 1975; 35:1050.
  • 31
    Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagher H, Portuese E, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 1993; 11:16911702.
  • 32
    Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86:230235.
  • 33
    Sagnelli E, Manzio G, Maio G, Pasquale G, Felaco FM, Filippini P, Izzo CM, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2:395397.
  • 34
    Nair PV, Tong MJ, Stevenson D, Roskamp D, Boone C. Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985; 5:812.
  • 35
    Perrillo RP, Campbell CR, Sanders GE, Regenstein FG, Bodicky CJ. Spontaneous clearance and reactivation of chronic hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med 1984; 100:4346.
  • 36
    Hoofnagle JH, Seeff LB. Natural history of chronic type B hepatitis. Prog Liver Dis 1982; 7:469479.
  • 37
    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001; 115:5862.
  • 38
    Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116:166169.
  • 39
    Marcello P, Fedele DM, Giovanni DGR, Alessandro S, Bruno P, Marco P, Aristide M, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99:724725.